Propanc Biopharma Targets February 2027 First-in-Human Phase 1b Study of PRP in Solid Tumors

With GMP manufacturing already underway and an HREC submission planned for November 2026, Propanc Biopharma is compressing the pre-trial workstream for PRP into a tight parallel-track structure that will test execution discipline across manufacturing, bioanalytics, and regulatory functions simultaneously.

The Melbourne-based company announced plans to initiate a multicenter, open-label Phase 1b first-in-human (FIH) study in February 2027, enrolling up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at sites across Australia. The two-part design pairs a dose-escalation phase (Part A) using a Bayesian Optimal Interval design with backfill (BF-BOIN) with a dose-expansion phase (Part B) targeting tumor-specific cohorts. Up to five dose levels are planned; Part A will identify the maximum tolerated dose and up to two recommended doses for optimization and expansion.

On the manufacturing side, a small-scale technology transfer run has been completed. Two scale-up runs are scheduled for September, with an engineering run planned for late October, a sequencing that leaves limited buffer before the November ethics submission window. Raw drug substance supply is secured following vendor qualification and audit. For QA leads tracking CMC readiness, the compressed timeline between the October engineering run and the HREC submission means any deviation or out-of-specification result at that stage carries material schedule risk.

Bioanalytical workstreams are running concurrently: PK method validation has commenced, anti-drug antibody assay development is underway, and in-use stability testing of the finished PRP formulation is scheduled. The Investigator's Brochure, a briefing document derived from it, and the clinical trial protocol are in preparation for distribution to Australian investigators ahead of feasibility assessment.

PRP will be administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle, with treatment continuing until a withdrawal criterion is met. The BF-BOIN design reflects current adaptive trial methodology and aligns with regulatory expectations for early-phase oncology studies where a predefined dose-limiting toxicity probability anchors dose escalation decisions.

Regulatory affairs teams at comparable small-cap sponsors will recognize the sequencing challenge: HREC submission in November 2026 against a February 2027 FIH start leaves roughly ten weeks for ethics review, site activation, and any late-stage CMC queries, a timeline that assumes no material findings from the October engineering run.

The February 2027 FIH start date now functions as the measurable checkpoint against which Propanc's parallel workstream execution will be assessed.

Source: Propanc Biopharma via GlobeNewswire, 9 September 2026.